MADRID — A Spanish pharmaceutical company says it’s setting up a new production line that would produce millions of Moderna’s coronavirus vaccine doses on European Union soil later this year.
Rovi’s existing facility in southern Spain’s Granada will receive an undisclosed investment to produce the active ingredient of Moderna’s jab, the company announced Monday in a press release.
The expected output will be up to 100 million vaccine doses per year starting in the third quarter of 2021, Rovi said, adding that the production will be destined to markets outside the United States.
The facility will be the first of its kind in the EU, adding to the production facilities that the Swiss biotech company Lonza has been operating there.
Rovi had until now operated production lines to fill vials with Moderna’s COVID-19 vaccine, but the active component had to be imported into the country.